GlobeNewswire: Advaxis Contains the last 10 of 181 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:52:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/04/19/962100/0/en/Advaxis-Appoints-Anthony-Lombardo-as-Chief-Business-Officer.html?f=22&fvtc=4&fvtv=20919Advaxis Appoints Anthony Lombardo as Chief Business Officer2017-04-19T12:00:00Z<![CDATA[PRINCETON, N.J., April 19, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Anthony A. Lombardo, an industry veteran with nearly 30 years’ experience in the field of life sciences, has joined the company as Chief Business Officer. Lombardo is a senior leader with extensive experience in helping global companies achieve significant growth.]]>https://www.globenewswire.com/news-release/2017/03/27/945356/0/en/Advaxis-Provides-Phase-1-Data-of-Higher-Dose-Axalimogene-Filolisbac.html?f=22&fvtc=4&fvtv=20919Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac2017-03-27T12:00:00Z<![CDATA[PRINCETON, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool that showed axalimogene filolisbac achieved durable response in a patient with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC).]]>https://www.globenewswire.com/news-release/2017/03/23/943488/0/en/EMA-Certification-Paves-the-Way-for-the-MAA-Submission-for-Axalimogene-Filolisbac-in-Metastatic-Cervical-Cancer.html?f=22&fvtc=4&fvtv=20919EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer2017-03-23T12:00:00Z<![CDATA[PRINCETON, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data.  The certification procedure involved a thorough scientific evaluation over several months of the quality (CMC) data and non-clinical data by the EMA’s Committee for Advanced Therapies (CAT).  After a positive opinion from CAT, EMA issued a certificate confirming that the CMC and non-clinical data comply with the standards that apply for evaluating the Marketing Authorization Application (MAA) of axalimogene filolisbac for the treatment of metastatic cervical cancer.  Advaxis is now positioned to file the complete MAA in the second half of 2017.]]>https://www.globenewswire.com/news-release/2017/03/15/937866/0/en/Advaxis-Presents-Oral-Late-breaking-Data-on-Phase-2-GOG-0265-Study-of-Axalimogene-Filolisbac-at-SGO-s-Annual-Meeting-on-Women-s-Cancer.html?f=22&fvtc=4&fvtv=20919Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer2017-03-15T11:00:00Z<![CDATA[- Achieved primary objective of 12-month survival rate, demonstrating axalimogene filolisbac is an active therapy in metastatic cervical cancer]]>https://www.globenewswire.com/news-release/2017/03/13/934952/0/en/Advaxis-to-Present-at-the-2017-Barclays-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20919Advaxis to Present at the 2017 Barclays Global Healthcare Conference2017-03-13T12:00:00Z<![CDATA[PRINCETON, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Sara Bonstein, Chief Financial Officer of Advaxis, will present a corporate overview at the 2017 Barclays Global Healthcare Conference being held in Miami on March 14-16.]]>https://www.globenewswire.com/news-release/2017/03/07/932818/0/en/Advaxis-Appoints-Al-Blunt-M-D-as-its-Vice-President-of-Medical.html?f=22&fvtc=4&fvtv=20919Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical2017-03-07T13:00:00Z<![CDATA[PRINCETON, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Al Blunt, M.D., has joined the company as Vice President of Medical. Dr. Blunt joins Advaxis from Covance, a leading global clinical research organization and drug development service company, where he was Executive Medical Director for Oncology.]]>Al Blunt, M.D. joins Advaxis as Vice President of MedicalAl Blunt, Advaxishttps://www.globenewswire.com/news-release/2017/03/06/931743/0/en/Advaxis-Announces-FDA-Acceptance-of-IND-for-Groundbreaking-Personalized-Neoepitope-Immunotherapy-ADXS-NEO.html?f=22&fvtc=4&fvtv=20919Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO2017-03-06T11:00:00Z<![CDATA[PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has indicated the Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in collaboration with Amgen, can proceed.]]>https://www.globenewswire.com/news-release/2017/03/02/930073/0/en/Advaxis-to-Host-Research-Reception-at-Society-of-Gynecologic-Oncology-Annual-Meeting-on-Women-s-Cancer.html?f=22&fvtc=4&fvtv=20919Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer2017-03-02T13:00:00Z<![CDATA[PRINCETON, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, will host a Research Reception during the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. The reception will be held from 5:30-7:00 p.m. ET on Monday, March 13, in National Harbor Room 15 at the Gaylord Convention Center in National Harbor, MD.]]>https://www.globenewswire.com/news-release/2017/02/27/927969/0/en/Advaxis-and-SELLAS-Announce-Licensing-Agreement-for-Development-of-WT1-Antigen-Targeting-Immunotherapy.html?f=22&fvtc=4&fvtv=20919Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy2017-02-27T13:00:00Z<![CDATA[PRINCETON, N.J., and HAMILTON, Bermuda, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on developing cancer immunotherapies, today announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm-based antigen delivery technology with SELLAS’ patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).]]>https://www.globenewswire.com/news-release/2017/02/06/914202/0/en/Advaxis-Announces-First-Patient-Dosed-in-Global-Phase-3-AIM2CERV-Trial-for-High-risk-Locally-Advanced-Cervical-Cancer.html?f=22&fvtc=4&fvtv=20919Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer2017-02-06T13:00:00Z<![CDATA[PRINCETON, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been enrolled and dosed in its AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence) trial, the only company-sponsored global phase 3 trial enrolling patients with  advanced stage cervical cancer.]]>